Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

A multimodal approach to accelerate drug discovery and development in Alzheimer’s disease

MAP-AD

Alzheimer’s disease (AD) is a major societal challenge, impacting up to one third of the population over 85 years old. The European Commission and various international bodies have repeatedly fostered research initiatives to prevent the development or stem the progression of the disease. Several recent phase 3 clinical trials have failed to show...
Funding Programme
Start Date
End Date
Total Funding
€ 257 620
European Countries Involved

A new brain-dedicated Positron Emission Tomography (PET) system to identify β-amyloid biomarker for the early diagnosis of Alzheimer’s disease and other causes of cognitive decline

CAREMIBRAIN

ONCOVISION is a Spanish SME specialised in design, development, production and commercialisation of organ-dedicated PET systems. Our company submits the present business innovation project with the overall objectives of (1) marketing an innovative brain-dedicated PET system to early diagnosis of Alzheimer’s disease (AD) and other causes of...
Funding Programme
Start Date
End Date
Total Funding
€ 4 393 596
European Countries Involved

A next-generation platform for catalysing pre-clinical development of drugs against Alzheimer’s and other degenerative diseases of old-age

NEW-AGE

Degenerative diseases of old age, including cardiovascular diseases, type II diabetes, and chronic respiratory conditions, have emerged as the major causes of death in EU countries. Of special concern are neurodegenerative conditions including Alzheimer’s and Parkinson’s, which have been described as the greatest unmet need facing modern medicine...

Funding Programme
Start Date
End Date
Total Funding
€ 149 961
European Countries Involved

A novel genetic assay for risk assessment of cognitive decline in Alzheimer’s Disease

variaTECT

Alzheimer’s Disease (AD) is the most prevalent cognitive disorder and progressively leads to complete brain dysfunction and degeneration. The number of people living with Alzheimer’s worldwide is now estimated at 46M, with this figure set to almost double by 2030 and more than triple by 2050 due to population aging. Current methods for early...
Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

A real-time and continuous brain monitoring system to record and track brain activity and extract biomarkers for neurological conditions

NS System

Neurological disorders, ranging from epilepsy, autism, dementias, Alzheimer’s and Parkinson’s diseases affect 1B people worldwide. Currently, Europe has the greatest percentage of population aged 65 or over (25%) and these numbers are expected to drastically grow (3% per year) increasing the population affected by brain disorders. Many neurological...
Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

A Single-Molecule Technology for Resolving Chaperone Action in Neurodegenerative Diseases

MicroSPARK

A range of debilitating neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, arise from the formation of amyloidogenic protein aggregates. Molecular chaperones can counteract aggregate formation, but their molecular action mechanisms remain poorly understood. This is chiefly due to the fundamental challenge of resolving...
Funding Programme
Start Date
End Date
Total Funding
€ 212 934
European Countries Involved

A smart, hybrid neural-computo device for drug discovery

NEUREKA

NEUREKA will bring a paradigm shift in drug discovery for neurological diseases, a sector that suffers multiple, repeated failures exacerbating the economical and societal burden of these incurable diseases. It will do so by addressing a crucial shortcoming: the lack of in vitro systems faithfully reproducing brain pathology that enable the...
Funding Programme
Start Date
End Date
Total Funding
€ 2 776 705
European Countries Involved

A strategy to investigate cell type-specific effects of non-coding regulatory elements to be applied in neurodegeneration research

NOJUNKDNA

I here propose a strategy to investigate cell type-specific effects of non-coding regulatory elements, which have been shown to play a fundamental role during the molecular pathophysiology of complex neurodegenerative diseases such as glaucoma in the eye or Alzheimer's or Parkinson's in the brain. By leveraging techniques from various scientific...
Funding Programme
Start Date
End Date
Total Funding
€ 171 461
European Countries Involved

A systems pharmacology approach to the discovery of novel therapeutics in Alzheimer´s disease

SYSPHARMAD

Alzheimer´s disease (AD) is the most common form of dementia, with over 35 million people suffering from it worldwide, and it constitutes a personal and societal tragedy of immense proportions. Fifty years of intense research have revealed many key elements of the biology of this neurodegenerative disorder. However, our understanding of the...
Funding Programme
Start Date
End Date
Total Funding
€ 1 296 000
European Countries Involved

A technology pLatform for the Assisted living of Dementia elDerly INdividuals and their carers

ALLADIN

The aim of the project is to utilise state-of-the-art in ICT in order to develop an integrated solution for the  self-management of dementia patients, and develop innovative tools to support this procedure. This  solution can be conceived as an integrated platform enabling distant monitoring of patient status and  facilitating personalised...
Funding Programme
Start Date
End Date
Total Funding
€ 1 980 757
European Countries Involved

A Treatment-Oriented Research Project of NCL Disorders as a Major Cause of Dementia in Childhood

DEM-CHILD

The DEM-CHILD project focusses on the main cause for childhood dementia in Europe, the neuronal ceroid lipofuscinoses (NCLs). The NCLs are neurodegenerative diseases characterized by dementia, blindness, epilepsy and physical decline leading to an early death of the patients. Since no cure is currently available, these disorders represent a serious...

Funding Programme
Start Date
End Date
Total Funding
€ 3 971 420
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).